( MENAFN - AETOSWire) (BUSINESS WIRE ) -- Kinaxis ® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Servier , a global independent pharmaceutical group, has selected Kinaxis to help revolutionize its supply chain planning capabilities with a view to accelerating time to market for its portfolio of life-saving drugs. One of the world's preeminent pharmaceutical companies, Servier has nearly 22,000 employees and a presence in 150 countries, with medicines targeting cancers, diabetes, as well as immune-inflammatory, neuropsychiatric, cardiovascular, and venous diseases.
The company's unique status as a laboratory governed by a non-profit foundation sees it invest upwards of 20% of its revenue each year from brand-name medicines into research and development, a strategy that has enabled it to accelerate research to discover new treatments faster for the benefits of patients. As part of the deployment, Kinaxis will enable Servier to plan more effectively and gain critical end-to-end visibility of its overall supply chain; a vital requirement as competing jurisdictional regulations, demand variability, and increased global disruptions play havoc with the pharmaceutical industry's mission to deliver high-quality products to customers at the lowest cost and with the shortest lead time. “One of Servier's principal ambitions is to be a resilient, growing, and sustainable company that's focused on a few areas where we can make the great.
